검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibitor (AI) |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.. Drug discovery remains constrained by high attrition rates and the fragmented evaluation of exposure, efficacy, and safety. Mechanistic models offer a biologically grounded framework for connecting these determinants across multiple levels of biological organization. This may help improve transl… |
Clinical Primary efficacy | ORR 27% |
Clinical ORR | 27.0% |
Clinical Result source | ClinicalTrials.gov NCT01446159 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibitor (AI) |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.. Drug discovery remains constrained by high attrition rates and the fragmented evaluation of exposure, efficacy, and safety. Mechanistic models offer a biologically grounded framework for connecting these determinants across multiple levels of biological organization. This may help improve transl… |
Clinical Primary efficacy | ORR 27% |
Clinical ORR | 27.0% |
Clinical Result source | ClinicalTrials.gov NCT01446159 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교